Selected research
Market Structure
Global Crigler-Najjar Syndrome Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Crigler-Najjar Syndrome Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for Crigler-Najjar Syndrome Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Crigler-Najjar Syndrome Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Crigler-Najjar Syndrome Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Crigler-Najjar Syndrome Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Crigler-Najjar Syndrome Drug include Audentes Therapeutics Inc, Genethon SA, International Stem Cell Corp and Promethera Biosciences SA, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Crigler-Najjar Syndrome Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Crigler-Najjar Syndrome Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Crigler-Najjar Syndrome Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Crigler-Najjar Syndrome Drug market size, projected growth trends, production technologies, key applications, and end-use industries.
Crigler-Najjar Syndrome Drug Segment by Company
Audentes Therapeutics Inc
Genethon SA
International Stem Cell Corp
Promethera Biosciences SA
Crigler-Najjar Syndrome Drug Segment by Type
ALXN-1540
AT-342
HepaStem
Others
Crigler-Najjar Syndrome Drug Segment by Application
Hospital
Clinic
Others
Crigler-Najjar Syndrome Drug Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Crigler-Najjar Syndrome Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Crigler-Najjar Syndrome Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Crigler-Najjar Syndrome Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Crigler-Najjar Syndrome Drug market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Crigler-Najjar Syndrome Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Crigler-Najjar Syndrome Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Crigler-Najjar Syndrome Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- ALXN-1540
- AT-342
- HepaStem
- Others
Applications
- Hospital
- Clinic
- Others
Companies covered
- Audentes Therapeutics Inc
- Genethon SA
- International Stem Cell Corp
- Promethera Biosciences SA
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Crigler-Najjar Syndrome Drug Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Crigler-Najjar Syndrome Drug Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Crigler-Najjar Syndrome Drug Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Crigler-Najjar Syndrome Drug Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Crigler-Najjar Syndrome Drug Market Dynamics
- 2.1 Crigler-Najjar Syndrome Drug Industry Trends
- 2.2 Crigler-Najjar Syndrome Drug Industry Drivers
- 2.3 Crigler-Najjar Syndrome Drug Industry Opportunities and Challenges
- 2.4 Crigler-Najjar Syndrome Drug Industry Restraints
3 Crigler-Najjar Syndrome Drug Market by Manufacturers
- 3.1 Global Crigler-Najjar Syndrome Drug Revenue by Manufacturers (2021-2026)
- 3.2 Global Crigler-Najjar Syndrome Drug Sales by Manufacturers (2021-2026)
- 3.3 Global Crigler-Najjar Syndrome Drug Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Crigler-Najjar Syndrome Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Crigler-Najjar Syndrome Drug Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Crigler-Najjar Syndrome Drug Manufacturers, Product Type & Application
- 3.7 Global Crigler-Najjar Syndrome Drug Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Crigler-Najjar Syndrome Drug Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Crigler-Najjar Syndrome Drug Players Market Share by Revenue in 2025
- 3.8.3 2025 Crigler-Najjar Syndrome Drug Tier 1, Tier 2, and Tier 3
4 Crigler-Najjar Syndrome Drug Market by Type
- 4.1 Crigler-Najjar Syndrome Drug Type Introduction
- 4.1.1 ALXN-1540
- 4.1.2 AT-342
- 4.1.3 HepaStem
- 4.1.4 Others
- 4.2 Global Crigler-Najjar Syndrome Drug Sales by Type
- 4.2.1 Global Crigler-Najjar Syndrome Drug Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Crigler-Najjar Syndrome Drug Sales by Type (2021-2032)
- 4.2.3 Global Crigler-Najjar Syndrome Drug Sales Market Share by Type (2021-2032)
- 4.3 Global Crigler-Najjar Syndrome Drug Revenue by Type
- 4.3.1 Global Crigler-Najjar Syndrome Drug Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Crigler-Najjar Syndrome Drug Revenue by Type (2021-2032)
- 4.3.3 Global Crigler-Najjar Syndrome Drug Revenue Market Share by Type (2021-2032)
5 Crigler-Najjar Syndrome Drug Market by Application
- 5.1 Crigler-Najjar Syndrome Drug Application Introduction
- 5.1.1 Hospital
- 5.1.2 Clinic
- 5.1.3 Others
- 5.2 Global Crigler-Najjar Syndrome Drug Sales by Application
- 5.2.1 Global Crigler-Najjar Syndrome Drug Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Crigler-Najjar Syndrome Drug Sales by Application (2021-2032)
- 5.2.3 Global Crigler-Najjar Syndrome Drug Sales Market Share by Application (2021-2032)
- 5.3 Global Crigler-Najjar Syndrome Drug Revenue by Application
- 5.3.1 Global Crigler-Najjar Syndrome Drug Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Crigler-Najjar Syndrome Drug Revenue by Application (2021-2032)
- 5.3.3 Global Crigler-Najjar Syndrome Drug Revenue Market Share by Application (2021-2032)
6 Global Crigler-Najjar Syndrome Drug Sales by Region
- 6.1 Global Crigler-Najjar Syndrome Drug Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Crigler-Najjar Syndrome Drug Sales by Region (2021-2032)
- 6.2.1 Global Crigler-Najjar Syndrome Drug Sales by Region (2021-2026)
- 6.2.2 Global Crigler-Najjar Syndrome Drug Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Crigler-Najjar Syndrome Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Crigler-Najjar Syndrome Drug Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Crigler-Najjar Syndrome Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Crigler-Najjar Syndrome Drug Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Crigler-Najjar Syndrome Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Crigler-Najjar Syndrome Drug Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Crigler-Najjar Syndrome Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Crigler-Najjar Syndrome Drug Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Crigler-Najjar Syndrome Drug Revenue by Region
- 7.1 Global Crigler-Najjar Syndrome Drug Revenue by Region
- 7.1.1 Global Crigler-Najjar Syndrome Drug Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Crigler-Najjar Syndrome Drug Revenue by Region (2021-2026)
- 7.1.3 Global Crigler-Najjar Syndrome Drug Revenue by Region (2027-2032)
- 7.1.4 Global Crigler-Najjar Syndrome Drug Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Crigler-Najjar Syndrome Drug Revenue (2021-2032)
- 7.2.2 North America Crigler-Najjar Syndrome Drug Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Crigler-Najjar Syndrome Drug Revenue (2021-2032)
- 7.3.2 Europe Crigler-Najjar Syndrome Drug Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Crigler-Najjar Syndrome Drug Revenue (2021-2032)
- 7.4.2 Asia-Pacific Crigler-Najjar Syndrome Drug Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Crigler-Najjar Syndrome Drug Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Crigler-Najjar Syndrome Drug Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 Audentes Therapeutics Inc
- 8.1.1 Audentes Therapeutics Inc Company Information
- 8.1.2 Audentes Therapeutics Inc Business Overview
- 8.1.3 Audentes Therapeutics Inc Crigler-Najjar Syndrome Drug Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 Audentes Therapeutics Inc Crigler-Najjar Syndrome Drug Product Portfolio
- 8.1.5 Audentes Therapeutics Inc Recent Developments
- 8.2 Genethon SA
- 8.2.1 Genethon SA Company Information
- 8.2.2 Genethon SA Business Overview
- 8.2.3 Genethon SA Crigler-Najjar Syndrome Drug Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 Genethon SA Crigler-Najjar Syndrome Drug Product Portfolio
- 8.2.5 Genethon SA Recent Developments
- 8.3 International Stem Cell Corp
- 8.3.1 International Stem Cell Corp Company Information
- 8.3.2 International Stem Cell Corp Business Overview
- 8.3.3 International Stem Cell Corp Crigler-Najjar Syndrome Drug Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 International Stem Cell Corp Crigler-Najjar Syndrome Drug Product Portfolio
- 8.3.5 International Stem Cell Corp Recent Developments
- 8.4 Promethera Biosciences SA
- 8.4.1 Promethera Biosciences SA Company Information
- 8.4.2 Promethera Biosciences SA Business Overview
- 8.4.3 Promethera Biosciences SA Crigler-Najjar Syndrome Drug Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 Promethera Biosciences SA Crigler-Najjar Syndrome Drug Product Portfolio
- 8.4.5 Promethera Biosciences SA Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Crigler-Najjar Syndrome Drug Value Chain Analysis
- 9.1.1 Crigler-Najjar Syndrome Drug Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Crigler-Najjar Syndrome Drug Production Mode & Process
- 9.2 Crigler-Najjar Syndrome Drug Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Crigler-Najjar Syndrome Drug Distributors
- 9.2.3 Crigler-Najjar Syndrome Drug Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst